Safety Concerns in Neurological Clinical Trials
Author Information
Author(s): Niazi Sarfaraz K.
Primary Institution: College of Pharmacy, University of Illinois, Chicago, IL, USA
Hypothesis
Are the clinical trials for monoclonal antibodies treating Alzheimer's disease violating patient rights and exposing them to high risks?
Conclusion
The study suggests that current clinical trials for Alzheimer's drugs are unethical without proof of sufficient brain bioavailability.
Supporting Evidence
- Monoclonal antibodies like lecanemab and aducanumab have shown poor efficacy in treating Alzheimer's disease.
- Clinical trials have reportedly violated patient rights and exposed them to high risks.
- High doses required for these drugs may lead to severe side effects and toxicity.
Takeaway
Some Alzheimer's drugs might not work well and could be dangerous, so scientists want to make sure they really help before testing them on people.
Methodology
The study reviews existing clinical trials and their ethical implications regarding patient safety and drug efficacy.
Potential Biases
Potential bias due to the author's involvement with the FDA and previous petitions against drug approvals.
Limitations
The study primarily focuses on the ethical concerns and does not provide new experimental data.
Participant Demographics
Participants included a high-risk subset predisposed to brain bleeding and swelling.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website